Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets

Xlife Sciences AG / Key word(s): Alliance/Partnership Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets 13.06.2025 / 17:42 CET/CEST Zurich, 13th of June 2025: Xlife Sciences AG («Xlife Sciences», SIX: XLS), a Swiss-based incubator and accelerator for life sciences innovation, has entered into a strategic Memorandum of Understanding («MoU») with JIPYONG LLC («JIPYONG»), a premier Korean law firm, and JIPYONG IP («JIPYONG IP»), a leading intellectual property advisory firm. This trilateral collaboration aims to enable high-potential Korean life sciences companies to access international capital markets, including potential listings, while strengthening their global market positioning.

The MoU was formally signed in Seoul by Oliver R. Baumann, Chief Executive Officer of Xlife Sciences AG, Mr. Haeng-Gyu Lee, Managing Partner of JIPYONG LLC, and Mr. Hyuk-Sung Kwon, Managing Partner of JIPYONG IP.

The collaboration encompasses five strategic pillars:

• Company Identification & Evaluation: Joint scouting and evaluation of promising Korean life sciences ventures across therapeutic areas and development stages.


• Investment Facilitation: Structuring and supporting direct and indirect investments in Korean life sciences companies.


• Capital Market Advisory: Providing regulatory, legal, and strategic guidance for cross-border listings.


• IP Strategy & Protection: Delivering patent portfolio assessments, monetization strategies, and ongoing IP support.


• Market Intelligence & Knowledge Sharing: Promoting a shared ecosystem of insights, trends, and commercialization know-how across regions.

This partnership represents a significant step toward globalizing the Xlife Sciences innovation model and leveraging Korea’s growing life sciences sector. It also positions JIPYONG and JIPYONG IP as key facilitators of global investment and commercialization for Korean biopharma and medtech innovators.